X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

AUPH

Closed

Aurinia Pharmaceuticals Inc

7.48
-0.99 (-11.69%)
Last Update: 01 Jul 2025 23:19:00
Yesterday: 8.47
Day's Range: 7.45 - 8.48
Send
When Written:
 
10.96
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes therapies to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia, Canada, and has a subsidiary in Rockville, Maryland, USA.

Aurinia's lead product is voclosporin, a drug candidate for the treatment of lupus nephritis, a potentially life-threatening autoimmune disease that affects the kidneys. The drug has completed Phase 3 clinical trials and is currently under review by regulatory authorities in the US, Europe, and Canada.

In addition to lupus nephritis, Aurinia is also developing voclosporin for the treatment of other autoimmune diseases, including focal segmental glomerulosclerosis (FSGS) and dry eye syndrome.

The company was founded in 1993 and went public in 2013. As of 2021, Aurinia Pharmaceuticals has a market capitalization of over $3 billion and employs over 200 people.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X